Keynote Speakers

Welcome Lecture

 

Dr Charles D. Bavington, Glycomar, UK

Keynote Speakers

 

Professor Raymond Andersen, Department of Chemistry, University British Columbia

Professor Terano Junji, Konan Women's University, Japan

Professor Jeremy Spencer, Department of Fodd and Nutritional Sciences, University of Reading

Professor Thomas Efferth, Institut fur Pharmazie und Biochemie, University of Mainz

Professor Rudolf Bauer, Institute of Pharmaceutical Sciences, Karl Franzens Universitaet

Francisco-Tomas Barberian, CEBAS-CSIC

_______________________________________________________________________________

Invited Speakers

 

Dr Charis Galanakis, Galanakis Laboratories, Greece

Prof. Dr. José Maurício Sforcin, Instituto de Biociências

Professor Gary Williamson, University of Leeds, UK

Professor Bin Xu, Virginia Technical College of Agriculture & Life Sciences, USA

Professor Hendrik Luesch, University of Florida, USA

Professor Michael Fenech, CSIRO, Adelaide, Australia

Professor WS Fred Wong, National University of Singapore, Singapore

Professor David Adelson, University of Adelaide, Australia

Prof. Juntian Zhang, Chinese Academy of Sciences, China

Professor Young-Joon Surh, Seoul National University, South Korea

Professor Shilin Chen, Institute of Chinese Materia Medica, Beijing, China

_______________________________________________________________________________

Industry Speakers

 

Dr Dennis Barron, Nestlé Institue of Health Sciences, Switzerland

Jessica Green,

Frank Hennequart, ALGAIA SAS, France

Dr Harriet Oldham, Neem Biotech, UK

François Sautel, Pierre Fabre, France

_______________________________________________________________________________

Dr Charles D. Bavington, GlycoMar

Charlie is a biochemist who has worked for 20 years in natural products research, specialising in marine natural products, with a focus on glycobiology and carbohydrate chemistry.

Following his PhD studies of proteoglycan metabolism in cartilage, at the University of Edinburgh, his first introduction to natural products was during Postdoctoral research at the Scottish Association for Marine Science. This jump from clinical research to marine natural products proved to be pivotal. The interdisciplinary project evaluated the functional properties, including anti-inflammatory activity, of glycans isolated from starfish, leading to the filing of patent. This lead to an opportunity to join a start up marine biotechnology company, Integrin Advanced Biosystems, which provide experience in developing commercial contract research services and of conducting commercial natural products R&D. In 2005 Charlie saw the opportunity to set up GlycoMar, a marine natural products business specialising in the discovery and development of novel functional glycans, with a focus on inflammation. The company has subsequently developed as a platform for generating novel polysaccharide products with a wide range of market applications.

Charlie’s scientific interests lie in studying structure functional relationships in polysaccharide products. His technology interests lie in developing novel production organism and systems for the manufacture of valuable polysaccharide products. He has a broader interest in promoting the commercial potential of marine natural products through innovative business models and disciplined entrepreneurship.

___________________________________________________________________

Professor Raymond Andersen, Department of Chemistry, University British Columbia

Dr. Andersen received his B.Sc. in chemistry from the University of Alberta, a M.Sc. in chemical physics from UC Berkeley, a Ph.D. in marine natural products chemistry from UC San Diego, and he was a post-doctoral Fellow in the chemistry department at MIT. He is a Professor of Chemistry at UBC and his research focuses on the discovery, synthesis, and biosynthesis of bioactive marine natural products and their potential as drug leads. Dr. Andersen is a Fellow of the Royal Society of Canada and he has received the Rutherford Medal in Chemistry from the Royal Society of Canada, the Chemical Institute of Canada Medal, the UBC Jacob Biely Research Prize, the Paul Scheuer Award in Marine Natural Products Chemistry, and the American Society of Pharmacognosy’s Farnsworth Award. He is a co-founder of Aquinox Pharmaceuticals and ESSA Pharma. Four experimental drugs based on natural products discovered and synthesized in Andersen’s lab have progressed to human clinical trials. One of these experimental drugs, AQX1125, is currently in phase III evaluation as a treatment for inflammatory bladder pain/interstitial cystitis and another, EPI-506, is currently in a phase I/II clinical trial for treating castration resistant prostate cancer.

_______________________________________________________________________________

Professor Terano Junji, Konan Women's University, Japan

Junji Terao, Ph.D. is a Professor in the Faculty of Nursing and Rehabilitation at the Konan Women’s University and Professor Emeritus of Tokushima University.  He received his Ph.D in Kyoto University and worked in Research Institute for Food Science, Kyoto University and Oklahoma Medical Research Foundation. In 1989, he started polyphenol research in National Food Research Institute, Ministry of Agriculture, Forestry and Fishery Japan.  In 1997, he joined Department of Nutrition, Tokushima University School of Medicine. His research interests are bioavailability and physiological function of dietary polyphenols and pathophysiological function of lipid peroxidation products. He published more than 240 peer-reviewed scientific papers. He organized and chaired  3th International Conference on Polyphenols and Health in Kyoto, Japan. He is a previous editor-in Chief of BioFactors and a previous president of Japanese Society of Food Factors.

_______________________________________________________________________________

Professor Jeremy Spencer, Department of Fodd and Nutritional Sciences, University of Reading

Dr Spencer received his PhD from King’s College London in 1997 and is currently Professor of Nutritional Biochemistry and Medicine at the University of Reading.  His initial work focused on the cellular and molecular mechanisms underlying neuronal death in Parkinson’s and Alzheimer’s disease. His recent interests concern how flavonoids influence brain health through their interactions with specific cellular signaling pathways pivotal in protection against neurotoxins, in preventing neuroinflammation and in controlling memory, learning and neuro-cognitive performance.  His work also pursues the actions of flavonoids on the vascular system, in particular their potential to reduce blood pressure, enhance vascular function and improve blood perfusion to the brain.

_______________________________________________________________________________

Professor Thomas Efferth, Institut fur Pharmazie und Biochemie, University of Mainz

Professor Dr. Prof. h. c. mult. Thomas Efferth is chair of the Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany. He is biologist by training (Technical University of Darmstadt, Germany). His doctoral thesis was completed at the German Cancer Research Center (DKFZ), Heidelberg, Germany (1990). Dr. Efferth was awarded the Ludolf-Krehl-Prize of the Southwest German Association for Medicine (1991), the Willmar-Schwabe-Award of the German Society for Medicinal Plant Research (2006), the citizen medal of the City of Heidelberg, Germany (2008), the CESAR Award for Translational Oncology (2011), and the SCENTEDdrop Award on medicinal and flagrant herbs (2015). He headed a research group for Pharmaceutical Biology at DKFZ (2005-2009) and was associate professor (apl) at the University of Heidelberg (2007-2009). In 2009, he took over the Chair of Pharmaceutical Biology (full professorship) at the Johannes Gutenberg University, Mainz. Furthermore, he is honorary professor at the Northeast Forestry University, Harbin, and at the Zhejiang Chinese Medical University, Hangzhou, China. Moreover, he is visiting professor at the Zhejiang University of Science and Technology, Hangzhou, China.

_______________________________________________________________________________

Professor Rudolf Bauer, Institute of Pharmaceutical Sciences, Karl Franzens Universitaet

Professor Dr. Rudolf Bauer studied pharmacy 1976‑1980 at the University of Munich; 1984 graduation as Ph.D. at the Institute of Pharmaceutical Bio­logy, University of Munich, under the supervision of Prof. Dr. H. Wag­ner; 1993 – 2002 Associate Professor at the Institute of Pharmaceutical Biology, University of Düsseldorf; since 2002 he is full professor of pharmacognosy at University of Graz, Austria, and since 2004 Head of the Institute of Pharmaceutical Sciences at University of Graz.

He has long experience in natural product chemistry, analysis and the bioassay-guided isolation of constituents from medicinal plants. He has published 340 research papers. For six years he has been president of the Society for Medicinal Plant and Natural Product Research (GA), and he has been acting as the founding president of GP-TCM Research Association. Currently he is President of the International Society of Ethnopharmacology.

Prof Bauer has been active in the development methods for quality control of Chinese herbs for more than 25 years. He is member of the expert group 13A and of the working group on TCM of the European Pharmacopoeia Commission; he is actively involved in the development of monographs of Chinese herbs for the European Pharmacopoeia; he was also member of the Traditional Asian Medicine Advisory Board of the Austrian Minister of Health. Together with Professor Litscher (Medical University of Graz) he is heading the TCM Research Center Graz.

_______________________________________________________________________________

Francisco-Tomas Barberian, CEBAS-CSIC

Francisco A. Tomás Barberán.  Ph.D. in Pharmacy, Valencia University (Spain), Research Professor of CSIC (Murcia, Spain). He is interested in the role of phenolic phytochemicals on food quality and human health. His current research aims to the identification of those food constituents that provide health benefits, the mechanisms by which they act and the effect of genetic, agronomic and processing factors on these metabolites, their bioavailability and the efficacy in humans and the role of gut microbiota in polyphenols metabolism. He has supervised 20 Ph.D. Thesis and has carried out research in laboratories from England (Reading), Switzerland (Lausanne), France (Lyon), and the USA (Davis). His research has also been oriented to the transfer to industry and he has registered 6 patents of which 3 have been licensed and derived products are actually in the market. He was awarded the Rhone-Poulenc Rorer Award by the Phytochemical Society of Europe in 1997, the Ramón Frial Award, on Food and Health Research in 2004, the ‘Carles Marti-Henneberg Award’ of the Danone Institute in 2006, and the DuPont Award of Science in 2012. He is Associate editor of the Journal of Agricultural and Food Chemistry of the American Chemical Society and a member of the Scientific Advisory Board of different Companies. He is the author of over 320 publications in scientific journals within the fields of phytochemistry, agricultural chemistry, and food science and nutrition. These articles have been cited over 15000 times with an H-index of 70. He has developed more than eighty competitive research projects and contracts with industry.

_______________________________________________________________________________

Dr Charis Galanakis, Galanakis Laboratories, Greece

 

Dr. Galanakis is an interdisciplinary scientist with a fast-expanding work that balances between food and sustainability, industry and academia. His research targets mainly the separation and recovery of functional macro- and micro-molecules from different food wastes and by-products, as well as their implementation as bioactive compounds in food and other products. He established the "Food Waste Recovery" term and Open Innovation Network (www.fwr.group) with an ultimate goal to inspire related professionals to extract high added-value compounds from wasted by-products in all stages of food production and re-utilize them in the food chain.

He is the executive director of Galanakis Laboratories, a chemical analysis and innovation centre, which was founded in 1924. Dr. Galanakis has over 15 years of experience in analyzing wine, food, beverages and environmental samples as well as at the consulting for related industries and local producers.  He serves as a Freelance editor in Elsevier since 2013, an editorial board member and subject editor of Food Research International (Elsevier) since 2012 and Food and Bioproducts Processing (Elsevier) since 2015.

He has published more than 90 scientific documents, including research articles, reviews and monographs in ISI Scientific Journals, book chapters and conference proceedings. He has edited 4 multi-author contributing books entitled as "Food Waste Recovery: Processing Technologies and Industrial Techniques" (2015), "Innovation Strategies in the Food Industry: Tools for implementation" (2016) and “Nutraceutical and Functional Food Components: Effects of Innovative Processing Techniques" (2017) and "Olive Mill Waste: Recent advances for the Sustainable Management" (2017).

_______________________________________________________________________________

Prof. Dr. José Maurício Sforcin, Instituto de Biociências

 

José Maurício Sforcin is a biologist and obtained his PhD in 1996 at the São Paulo State University – UNESP, Brazil.

In 2006, he became an associate professor at the Biosciences Institute, where he is now head of the Lab “Immunomodulation by Natural Products”.

His research interests are in the role of natural products (predominantly propolis and its constituents) in Applied Immunology and Microbiology.

 

_______________________________________________________________________________

Professor Gary Williamson, University of Leeds, UK

Professor and Chair at the University of Leeds, UK; previously Head of Group at Nestle Research Center, Lausanne, and Institute of Food Research, Norwich. Research interests in how dietary polyphenols are absorbed and the mechanisms by which they reduce the risk of cardiovascular disease/diabetes, especially effects on sugar metabolism. Has published more than 340 peer-reviewed scientific papers, and is ISI/Thomson Reuters highly cited researcher with h index of 74. Has supervised 46 previous and current PhD students, and involved in over 25 human intervention studies. Holder of a European Research Council Advanced Grant, Fellow of the Royal Society of Chemistry, previously Editor-in Chief of the Royal Society of Chemistry journal, Food and Function, and organiser and chairman of 4th International Conference on Polyphenols and Health in Harrogate, UK.

_______________________________________________________________________________

Professor Bin Xu, Virginia Technical College of Agriculture & Life Sciences, USA

Dr. Bin Xu received his BSc in Chemistry at Fudan University in Shanghai, China and his Ph.D. in Biochemistry and Diabetes Research from Case Western Reserve University School of Medicine in Cleveland, Ohio, USA. He then performed postdoctoral research fellowship in the area of Molecular Immunology at Fred Hutchinson Cancer Research Center, Seattle, Washington. Since 2011, he has been faculty in the Department of Biochemistry at Virginia Tech College of Agriculture and Life Sciences, directing protein-ligand interactions and molecule medicine research including natural product drug discovery. His laboratory uses multidisciplinary approaches, including chemistry, biochemistry, structural, molecular and cellular biology, high throughput screening, ligand discovery and design, nanotechnology, and rodent model of diseases. Systems of particular interest link to diabetes, obesity, and neurodegeneration. He has been invited as speaker to over fifty international conferences and academic institutions and served on multiple occasions in chairing international conferences in the areas of chemical biology and medicinal chemistry. His laboratory currently has active projects including natural product-based “Prevention of amylin amyloidosis in type 2 diabetes by botanical baicalein”, “Molecular mechanisms of amylin as a novel contributor for Alzheimer’s disease”, and “Identification of molecular target-based phytonutrients to reduce fat deposit in broiler chicks”.

_______________________________________________________________________________

Professor Hendrik Luesch, University of Florida, USA

Hendrik Luesch received his Diplom in Chemistry at the University of Siegen (Germany) in 1997. He studied marine natural products chemistry at the University of Hawaii at Manoa and obtained his Ph.D. with Professor Richard E. Moore in 2002.  He undertook three years of postdoctoral studies as an Irving S. Sigal Fellow at The Scripps Research Institute with Professor Peter G. Schultz in functional genomics and chemical biology. Since 2005 he has been faculty at the University of Florida and is currently Professor and Chair of the Department of Medicinal Chemistry.  He holds the endowed Debbie and Sylvia DeSantis Chair in Natural Products Drug Discovery and Development and leads a multidisciplinary marine natural products program that integrates isolation, synthesis, pharmacology, mechanism of action and early development studies.  He is also co-founder and CSO of Oceanyx Pharmaceuticals, Inc.

http://pharmacy.ufl.edu/faculty/hendrikluesch/

http://www.oceanyxpharma.com/

_______________________________________________________________________________

Professor Michael Fenech, CSIRO, Adelaide, Australia

Professor Michael Fenech is recognised internationally for his research in nutritional genomics and genetic toxicology and for developing the cytokinesis-block micronucleus (CBMN) assay which is a standard method used internationally to measure DNA damage in human cells. The CBMN assay has been endorsed by the International Atomic Energy Agency and the OECD for in vivo radiation biodosimetry and in vitro testing of genotoxins respectively. His key goal is to determine the nutritional and environmental requirements for DNA damage prevention. In 2003 Dr Fenech proposed a novel ageing and disease prevention strategy based on personalised diagnosis and prevention of DNA damage by appropriate diet/life-style intervention, which has led to the Genome Health Clinic concept. In 2003-2009 his laboratory further developed the CBMN assay into a 'cytome' assay consisting of six complementary biomarkers of DNA damage and cytotoxicity which is now published in Nature Protocols. He co-founded the HUMN projects on micronuclei in human populations (www.humn.org) and is a member of the coordinating group and co-founder of the Micronutrients Genomics Project which he has been leading since July 2011. His research is currently also focused on (i) the impact of nutrition and psychological stress on telomere integrity and (ii) personalised nutrition for dementia prevention and cancer growth control. In 2014 he was elected Foundation President of the Asia-Pacific Nutrigenomics and Nutrigenetics Organisation (APNNO). Since 2010 he has been an invited speaker at 45 international conferences (9 plenary lectures). His H-index is 73 based on 24,159 total career citations according to Google Scholar.

_______________________________________________________________________________

Professor WS Fred Wong, National University of Singapore, Singapore

Dr. Wong received his BPharm (cum laude) from the St. Johns’ University in New York and his PhD from the Ohio State University in Columbus, Ohio. He then moved to Lilly Research Laboratories at Indianapolis to be a postdoctoral scientist with research focus on respiratory drug development and then to Respiratory Medicine Division at the Brigham and Women’s Hospital in Boston as a Research Fellow in Medicine. Dr. Wong then joined the Department of Pharmacology at The National University of Singapore (NUS), and since built the Respiratory Pharmacology Laboratory. The long-term goal of his research program is to discover and develop pharmacological strategies for the treatment of asthma and COPD. Bioactive molecules isolated from nutritional food and natural products are a rich source of novel therapeutics or for drug repositioning. Dr. Wong’s laboratory was the first to report the protective effects of genistein, an isoflavone isolated from soy beans, in a guinea pig asthma model. His laboratory was the first to report the protective effects andrographolide, a labdane dieterpenoid isolated from the herb Andrographis paniculata, in a mouse asthma model and in a cigarette smoke COPD mouse model. His laboratory has repositioned artesunate, an anti-malarial drug, as an anti-inflammatory agent for asthma and COPD. There has been a long debate on which vitamin E isoform, a-tocopherol or g-tocotrienol, is the effective antioxidant for asthma and COPD. My laboratory has recently answered this question by showing g-tocotrienol has superior antioxidant and anti-inflammatory effects in a HDM mouse asthma model.

phcwongf@nus.edu.sg / fred_wong@nuhs.edu.sg

_______________________________________________________________________________

Professor David Adelson, University of Adelaide, Australia

David Adelson is Professor and Chair of Bioinformatics and Computational Genetics and Zhendong Chair of Molecular Traditional Chinese Medicine in the School of Biological Sciences at the University of Adelaide.  Prof. Adelson is currently Director of the Zhendong Centre of Molecular Traditional Chinese Medicine. The philosophy of the Zhendong Centre is that complex molecular effects of TCM preparations will provide a molecular basis for understanding the mode of action of TCM and support integration into Western medicine.  A major approach to this work uses transcriptome analysis to identify entire pathways or co-expression sub-networks in cancer cells that are altered as a result of a particular TCM preparation, Compound Kushen Injection. 

Prof. Adelson’s current research also focuses on the non-coding portions of animal genomes, such as regions used to transcribe ncRNAs (piRNAs and lncRNAs) and the computational analysis of repetitive, so called “Junk DNA”, in order to understand large scale evolutionary/structural changes in animal genomes.  He has led the analysis of repetitive DNA for the cow and horse genome sequencing consortia and his lab is currently working on the Elephant, Echidna, Tuatara and Pogona repetitive DNA analyses. 

Prior to moving to Adelaide in 2007, Prof Adelson worked at Texas A&M University from 2001, and before that worked for CSIRO from 1988.  Dave obtained his PhD in Biomedical Sciences (Biochemistry), from the John A Burns School of Medicine at the University of Hawaii at Manoa in 1985 and carried out postdoctoral research at Duke University. 

_______________________________________________________________________________

Prof. Juntian Zhang, Chinese Academy of Sciences, China

Prof Zhang Jun-tian was born in June 1931, China. He has been engaged in the pharmacological research in the Institute of Materia Medica, Chinese Academy of Medical Sciences (CAMS) for more than half of century since graduated from Dalian Medical College. Prof Zhang is the former president of Chinese Pharmacological Society (CPS) and former director of institute of material medica, CAMS. Now, he is the advisor of many journals and scientific societies, such as Acta pharmacological sinica, Division of neuropharmacology, division of tonic pharmacology of CPS, and so on.

During Prof zhang’s research period, He got fruitful achievements, including published more than 300 papers, and cited more than 1000 times by other studies; Edited more than 20 books, such as modern pharmacology methods, neuropharmacology, et al. Developed 9 kinds of drugs successfully and 2 kinds of novel-drugs is in the research and development stage; Won several prize including second prize of National Science and Technology Progress Awards in China, first prize of Ministry of Education and so on. Cultivation of more than 50 Ph.D or postdoctal fellows.

_______________________________________________________________________________

Professor Young-Joon Surh, Seoul National University, South Korea

Professor Young-Joon Surh is currently Director of Tumor Microenvironment Global Core Research Center, Seoul National University, Korea. He graduated from College of Pharmacy, Seoul National University with BS and MS, and earned a PhD degree at the University of Wisconsin-Madison. Professor Surh then had postdoctoral training at the Massachusetts Institute of Technology. In 1992, he was appointed as Assistant Professor at Yale University School of Medicine. Since relocating to Seoul National University in 1996, Dr. Surh has been investigating the molecular mechanisms of cancer prevention with anti-inflammatory phytochemicals. He is currently Associate Editor of Molecular Carcinogenesis, Toxicology & Applied Pharmacology, and Free Radical Research, and Editorial Board member of Antioxidants & Redox Signaling, International Journal of Cancer, Mutation Research, Life Sciences, Food and Chemical Toxicology, Genes and Nutrition, Molecular Nutrition and Food Research, and more recently Precision Oncology published by Nature Publishing Group. Prof. Surh has published more than 280 papers in peer-reviewed international journals and about 70 invited editorials, reviews and book chapters. The total number of citations of his publications is more than 17,000 (excluding self-citations). He published a seminal review article, titled cancer chemoprevention with dietary phytochemicals, in Nature Reviews Cancer which has been cited more than 1,600 times. The H-Index reported by Thomson Reuter of Web Knowledge is 68. He received numerous awards including Elizabeth and James A. Miller Distinguished Scholar Award from Rutgers University, McCormic Science Institute Award from American Society for Nutrition (2009), and the Distinguished Scientist Award given by President of South Korea.

_______________________________________________________________________________

Professor Shilin Chen, Institute of Chinese Materia Medica, Beijing, China

Professor Shilin, Chen, the Director of the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, now also works as the Director of the World Health Organization Collaborating Center for Traditional Medicine, Academician of International Academy of Sciences for Europe and Asia, Vice President of the Consortium for Globalization of Chinese Medicine, Visiting Professor of Tokyo University of Pharmacy and Life Sciences, Team Leader of Changjiang Scholars and Innovation Team, Ministry of Education (MOE),  He has written some related works, including Standard DNA barcodes of Chinese Materia Medica in Chinese Pharmacopoeia..  Prof. Chen has proclaimed that the elucidation of the G. lucidum genome made the organism a potential model system for the study of secondary metabolic pathways and their regulation in medicinal fungi. He has so far published totally more than 400 academic works on famous academic journals, such as Nature Commun, Plant J and PNAS. His academic works have been cited more than 10,000

_______________________________________________________________________________

Dr Dennis Barron, Nestlé Institue of Health Sciences, Switzerland

Dr Denis Barron is the head of the Natural Bioactives & Screening department at Nestlé Institute of Health Sciences (NIHS), Lausanne, Switzerland. He first studied Pharmacy at the Universities of Clermont-Ferrand and Grenoble. He obtained his PhD in 1987 from Concordia University (Montreal, Canada), where he worked on the phytochemical characterization, the chemical synthesis and the enzymatic synthesis of plant sulfated flavonoid. Then he entered the French institute of Agriculture (INRA) in Dijon as a research assistant in the field of aroma research. In 1989, he got an assistant professorship in Pharmacognosy at the school of Pharmacy of Grenoble (France), and developed a number of synthetic tools for the organic synthesis of isoprenoid flavonoids. In 1994, he was nominated full professor in plant biochemistry at University of Lyon (France). His research interest was oriented towards the discovery of natural inhibitors of cellular efflux pumps that are involved in chemoresistance and nutrient absorption such as P-glycoprotein and MRP. Dr Barron research activities, at the boarder of pharmacy and nutrition, gave him the opportunity to join Nestlé Research Center (NRC) in Lausanne in 2003. At NRC his research activities were oriented towards the human metabolism of dietary polyphenols, and towards the characterization of bioactive compounds from food ingredients. In 2012, he moved to NIHS. His current activities aim at identifying natural food products and extracts that are relevant in the prevention and the treatment of metabolic, brain, and gastro intestinal diseases.

_______________________________________________________________________________

Dr Harriet Oldham, Neem Biotech, UK

Harriet obtained her first degree in pharmacology from Aberdeen University and a PhD from the University of Bath. She has worked across academia and industry and in both Big Pharma and biotech SMEs within her industry roles. This includes time at GSK, Servier and Shire.

Harriet has direct experience of positions spanning all aspects of the drug design and development process from the laboratory through to specific project planning and monitoring and, more broadly, operational management. She has served as team representative on multidisciplinary committees resulting in a well-established understanding of the role and contributions of all scientific disciplines involved in taking a drug through the early stages of the development process.

This blend of access to multidisciplinary input and wide ranging exposure to different business models has led to a somewhat unique ability to balance the viewpoints and requirements of all stakeholders in the drug development process. 

Harriet thrives on the challenge of getting the best out of science to discover new and better ways of meeting unmet medical need.

She currently holds the role of Drug Development Scientist at Neem Biotech, where she has responsibility for overseeing operational aspects of Neem’s flagship compound being prepared for a first-in-man clinical trial.

_______________________________________________________________________________